GEOVAX LABS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
GEOVAX LABS, INC. (GOVX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 200.00% for the 6-month period ending 2026-06-30, per its S-1 filed 2026-09-17.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-09-17
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 160.00%, a 0.00% change from fiscal 2022.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 160.00%, a 88.68% increase from fiscal 2021.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2021 was 84.80%, a 122.22% increase from fiscal 2020.
- GEOVAX LABS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2020 was 38.16%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|
| 2026-06-30 | 200.00% S-1 · filed 2026-09-17 | |
| 2025-12-31 | 179.30% S-1 · filed 2026-09-17 | |
| 2024-12-31 | 204.20% S-1 · filed 2026-09-17 | |
| 2023-12-31 | 160.00% 10-K · filed 2024-02-29 | |
| 2022-12-31 | 160.00% 10-K · filed 2023-03-23 | |
| 2021-12-31 | 84.80% 10-K · filed 2023-03-23 | |
| 2020-12-31 | 38.16% 10-K · filed 2022-03-09 | |
| 2018-12-31 | 71.34% 10-K · filed 2020-03-24 | |
| 2017-12-31 | 89.73% 10-K · filed 2019-03-26 | |
| 2016-12-31 | 88.72% 10-K · filed 2019-03-26 | |
| 2015-12-31 | 91.43% 10-K · filed 2018-03-23 | |
| 2014-12-31 | 94.88% 10-K · filed 2017-03-24 | |
| 2013-12-31 | 96.60% 10-K · filed 2016-03-16 | |
| 2012-12-31 | 105.20% 10-K · filed 2015-03-20 | |
| 2011-12-31 | 111.20% 10-K · filed 2014-03-14 | |
| 2010-12-31 | 112.90% 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B |